4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

• 3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks
• In the recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and 4FRONT-2 patient populations, 87% required 0-1 supplemental injection and 80% were injection-free through 52 weeks
• Durable and stable aflibercept expression demonstrated across all 3E10 vg/eye PRISM cohorts, with up to two years of follow-up
• 4D-150 continues to be well tolerated, with up to three years of follow-up
• 4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively
• Company to host webcast on Monday, February 10, 2025 at 8:00 a.m. ET

EMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. Additional data were provided on the durability of aflibercept expression for up to two years. The data were presented by Dante Pieramici, M.D., in an oral presentation titled “Phase 2b Population Extension Cohort Evaluating 4D-150 in Neovascular Age-Related Macular Degeneration: 52-Week Results” at Angiogenesis, Exudation, and Degeneration 2025.

“We believe 4D-150 has paradigm-shifting potential. 4D-150 is designed to achieve favorable tolerability and robust and durable multi-year efficacy following routine intravitreal administration that enables seamless integration into retina clinics,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “The data from the PRISM clinical trial, which evaluated wet AMD patients with a broad range of disease severity and duration, and the initial data from SPECTRA in diabetic macular edema (DME), demonstrate 4D-150’s potential to become the first backbone therapy forming the foundation for the treatment of vascular retinal diseases. The ability to deliver disease control with long-lasting freedom from frequent bolus injections addresses the primary unmet need for patients and physicians.”